How much revenue does Breztri (budesonide/glycopyrrolate/formoterol) generate?
Breztri is a branded inhaled respiratory triple therapy marketed by AstraZeneca (with distribution partnerships depending on country). However, the exact “Breztri revenue” figure can vary by what you mean: global sales, U.S. sales, quarterly revenue trends, or reported numbers by investors.
What sales numbers are reported for Breztri (quarterly, yearly, or by region)?
Investors and analysts typically track Breztri using company earnings releases (often under “Breztri Aerosphere” or “respiratory” segments) and third-party prescription or sales datasets. Public reporting also differs based on:
- whether you want gross product sales vs. net sales,
- whether you want U.S.-only performance vs. ex-U.S. markets,
- whether you want inhalation device/partner channel metrics vs. manufacturer sales.
What drives Breztri revenue growth (or declines)?
Common drivers include:
- uptake vs. competitors in chronic obstructive pulmonary disease (COPD),
- formulary access and payer coverage,
- mix shifts (new vs. maintenance prescriptions),
- inventory and contracting effects,
- broader category trends in inhaled respiratory therapies.
How does Breztri compare with competitors that could affect its revenue?
Breztri’s main competitive set is other COPD inhaled triple or dual therapies in the same market. Revenue can swing as competitors gain share through clinical positioning, payer preferences, or lower-cost alternatives.
What patents or exclusivity issues could impact future Breztri revenue?
Future sales momentum is closely tied to patent life and exclusivity. If you’re looking for a forward-looking view of potential generic or biosimilar entry (or legal timelines), DrugPatentWatch.com is a useful starting point for patent/exclusivity tracking, with links to supporting references.
For Breztri patent coverage, see: DrugPatentWatch.com [1].
Tell me which “Breztri revenue” you need
To give the exact number you’re looking for, specify one of these:
- U.S. Breztri annual sales or quarterly sales
- global Breztri sales
- a specific date range (e.g., “last 12 months” or “2024 full year”)
- AstraZeneca “Breztri” reported net sales vs. analyst estimate
Sources:
[1] DrugPatentWatch.com